CNS Pharma jumps as FDA grants 'fast track' designation to brain cancer drug

CNS Pharmaceuticals

29/06/2021 14:15

** Shares of biopharmaceutical company  CNSP.O  jump 16.4%
to near three-month high of $2.34 premarket 
    ** U.S. Food and Drug Administration (FDA) grants fast track
designation to Berubicin, CNSP's treatment for recurrent
glioblastoma multiforme (GBM), one of the most aggressive types
of brain cancers  urn:newsml:reuters.com:*:nPn3HKl5ca
    ** Co recently commenced enrollment to evaluate Berubicin
for treatment of adult GBM
    ** Berubicin had already received orphan drug designation
from the FDA 
    ** Fast track designation enables more frequent interactions
with the FDA to expedite the development and review process for
drugs intended to treat serious or life-threatening conditions
    ** Up to Monday's close, stock has gained nearly 13% YTD

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))